HSEPID · Investigating the genetic architecture and pathogenesis of of Herpes Simplex encephalitis susceptibility
FP7 — People (Marie Curie Actions)
- Duration
- 2012-01-12 → 2014-01-11
- EU contribution
- €30,000
- Participants
- 1
- Scheme
- MC-ERG
Lines connect the coordinator with its partners.
Results in brief
Investigating the genetic architecture and pathogenesis of of Herpes Simplex encephalitis susceptibility
Publishable Summary Infection by the human herpes simplex virus-1 (HSV-1) is among the most common childhood infections usually causing cold sores. Although HSV-1 usually results in mild disease, very rarely, infection can be life threatening. One such rare but serious complication is a brain infection known as encephalitis. Childhood herpes simplex encephalitis (HSE) is known to result from genetic deficiencies of a particular antiviral pathway (the TLR3-IFN pathway). Patients with these deficiencies are unable to produce protective factors (IFNs) following virus infection. However the known genetic deficiencies account for >10% of HSE cases in our study cohort. There are two main objectives to this proposal: (i) To identify other gene(s) responsible for protection against HSV-1 infection in childhood HSE patients, (ii) To explore anti-HSV1 immunity in the neuronal cells of HSE patients. We have focused on studying one particular patient with HSE, P1, whose cells showed a TLR3 pathway defect. We have successfully identified a novel gene, using whole exome sequencing technology, previously not known to be involved in the HSE-causing TLR3 pathway. P1 is heterozygous for this missense mutation found in a gene involved in the endoplasmic pathway. The mutation is novel and predicted to have a deleterious impact on the protein. Initial studies knocking down the gene in control cells show impaired production of protective antiviral IFNs following stimulation of the TLR3 pathway. Confirmation and further characterization of the gene is ongoing. There have been unexpected delays in the generation of neuronal cells, and we have shifted our focus to explore the role of another cell autonomous antiviral mechanism in HSV1 immunity: autophagy. Autophagy is involved in the recycling of damaged cellular components, and in elimination of unwanted viral infections. Recently, genes in the TLR3 pathway were also found to play a role in the autophagy pathway. However the role of autophagy has not been studied in HSE patients. We proposed that autophagy plays an important role in preventing brain damage caused by HSV1 infections. We have studied the process of autophagy following viral infection in these patients’ skin cells to understand its role in disease. We plan to further study the role of this pathway in the patients’ brain cells using a state-of-the-art method of culturing skin cells into brain cells to study patients’ brain cells in a non-invasive manner. The identification of genes and pathways involved in disease will improve our understanding of human herpes virus infections. Results from this study may lead to the development of new drug targets for HSV1. It may also lead to the development of therapies in the prevention of brain or nerve damage which remains a major cause of morbidity in HSV1 diseases. The results of the project are of high impact and have been the subject another grant proposal that I have been successfully awarded. This not only demonstrates the value of the work but has also enabled me to fully integrate into the Host institute as an independent researcher.
Data: CORDIS, © European Union
Project objective
Childhood herpes simplex encephalitis (HSE) is a potentially life-threatening complication of primary infection by herpes simplex virus-1 (HSV-1), a common virus that is innocuous in most children. HSE is the most common sporadic viral encephalitis in Western countries and acyclovir-treated patients often suffer from severe neurological sequels. The pathogenesis of HSE remained unknown until the recent discoveries of Mendelian single-gene mutations specifically impairing immunity to HSV-1 at least in a subset of children suffering from HSE. We have identified mutations in TLR3, UNC93B, TRIF and TRAF3 in patients with isolated HSE, suggesting that impaired type I interferon (IFN) production upon stimulation of TLR3 by dsRNA viral intermediates in the CNS underlies the pathogenesis of HSE in these patients. Despite the identification of these genes, only a minority of the patients tested carried these genetic defects. Hence we hypothesize that childhood HSE is a genetically heterogeneous disease and that other single gene inborn errors of immunity may explain HSE in other patients. As a first objective, we hope to identify novel HSE-causing genes following a candidate gene approach in patients with a cellular phenotype. The TLR3-IFN pathway will be tested and the known genes sequenced. For those without any mutations in known genes, alternative approaches such as cDNA complementation and RNA sequencing will be carried out. In addition, we also aim to understand the cellular basis of the pathogensis of HSE as most our studies have been carried out on patients’ fibroblasts. We hope to characterize the TLR3-dependent type I IFN production in response to dsRNA and HSV-1 in CNS resident cells by differentiating patient-derived fibroblast induced pluripotent stem (iPS) cells into neurons, oligodendrocytes, and astrocytes. Investigating the anti-HSV-1 immunity in the relevant CNS cells types will be important in furthering our understanding of HSE pathogenesis.""
Original text from CORDIS.
Participants
- IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE · LondonCoordinatorUnited Kingdom
Links
Data: CORDIS, © European Union
